Mark McPartland Net Worth

Mark McPartland biography

Mark A. McPartland serves as Vice President - Corporate Development of the Company. Mr. McPartland has served as our Vice-President, Corporate Development since October 2016. Mr. McPartland previously served as the Vice President of Corporate Development and Communications at Stellar Biotechnologies, Inc. (now Edesa Biotech, Inc. (NASDAQ: EDSA)), from November 2013 to September 2016. While at Stellar, Mr. McPartland was responsible for transforming and expanding its capital markets and corporate communications strategy, while also supporting its global business development activities. From September 2011 to November 2013, Mr. McPartland served as Senior Vice President at MZ North America, a subsidiary of MZ Group, a global leader in investor relations and corporate communications, and from January 2005 to January 2011, he served as Vice President and Partner at Alliance Advisors, LLC where he specialized in the implementation of capital markets strategy, market positioning and financial communications, and Regional Vice President of Hayden Communications, Inc. where he led investor relations and corporate communications programs for micro and small cap companies. Mr. McPartland received his Bachelors in Business Administration and Marketing from Coastal Carolina University.

What is the salary of Mark McPartland?

As the Vice President - Corporate Development of Vistagen Therapeutics, the total compensation of Mark McPartland at Vistagen Therapeutics is $479,988. There are 8 executives at Vistagen Therapeutics getting paid more, with Shawn Singh having the highest compensation of $933,667.

How old is Mark McPartland?

Mark McPartland is 54, he's been the Vice President - Corporate Development of Vistagen Therapeutics since 2017. There are 12 older and 3 younger executives at Vistagen Therapeutics. The oldest executive at Vistagen Therapeutics Inc. is Jon Saxe, 84, who is the Independent Chairman of the Board.

What's Mark McPartland's mailing address?

Mark's mailing address filed with the SEC is C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Vistagen Therapeutics

Over the last 8 years, insiders at Vistagen Therapeutics have traded over $147,300 worth of Vistagen Therapeutics stock and bought 1,944,506 units worth $18,208,989 . The most active insiders traders include Healthcare Capital Partners..., Capital Lp Commodore и Jon S Saxe. On average, Vistagen Therapeutics executives and independent directors trade stock every 88 days with the average trade being worth of $378,372. The most recent stock trade was executed by Capital Lp Commodore on 7 August 2023, trading 775,756 units of VTGN stock currently worth $17,958,751.

What does Vistagen Therapeutics do?

we have developed a versatile stem cell technology platform based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed, human cells which can be used to create novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue and cell therapy. we believe our stem cell technology platform, human clinical trials in a test tube™, can provide clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.

Vistagen Therapeutics executives and stock owners

Vistagen Therapeutics executives and other stock owners filed with the SEC include:

• Shawn Singh,
  Chief Executive Officer, Director
• Shawn K. Singh J.D.,
  CEO & Director
• H. Ralph Snodgrass,
  President, Founder, Chief Scientific Officer, Director
• Jerrold Dotson,
  Chief Financial Officer, Vice President, Secretary
• Mark Smith,
  Chief Medical Officer
• Dr. Mark A. Smith M.D., Ph.D.,
  Chief Medical Officer
• Dr. H. Ralph Snodgrass Ph.D.,
  Founder, Pres & Chief Scientific Officer
• Jerrold D. Dotson CPA, CPA,
  CFO, VP & Sec.
• Mark McPartland,
  Vice President - Corporate Development
• Jon Saxe,
  Independent Chairman of the Board
• Ann Michelle Cunningham M.B.A.,
  Chief Commercial Officer & Director
• Valter Pinto,
  Investor Relations
• Brian Underdown,
  Independent Director
• Jerry Gin,
  Independent Director
• Ann Cunningham,
  Independent Director
• Dr. Mark J. Ginski,
  Sr. VP and Head of Chemistry, Manufacturing & Controls
• Mark Adrian McPartland,
  VP of Corp. Devel.
• Healthcare Capital Partners...,
  
• Margaret M Fitz Patrick,
  
• Joanne Curley,
  
• Mary L. Rotunno,
  
• Mark J Ginski,
  SENIOR VP, HEAD OF CMC
• Joshua S. Prince,
  Chief Operating Officer
• Cynthia Lynn Anderson,
  CHIEF FINANCIAL OFFICER
• Capital Lp Commodore,
  10% owner
• Reid G. Adler,
  CHF CORP DEVEL OFF, GEN COUNS